Enveric Biosciences (OTCMKTS:SPZR) is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics derived from psychedelic and cannabinoid compounds to address central nervous system (CNS) disorders and oncology supportive care. Headquartered in Houston, Texas, with research partnerships and operations extending into North America and Europe, Enveric aims to leverage proprietary formulations of naturally occurring and synthetic psychedelics to create targeted treatment options for patients with acute and chronic conditions that currently lack effective medical therapies.
The company’s pipeline includes several lead programs in various stages of clinical development. EB-101 (psilocybin) is being evaluated for the treatment of anorexia nervosa, with early-stage trials designed to assess safety, tolerability, and potential therapeutic benefit. EB-102, a proprietary formulation of N,N-dimethyltryptamine (DMT), is under investigation for opioid withdrawal and substance use disorders. Additionally, EB-202, a synthetic psilocybin analog, is being developed to support neutrophil recovery in patients experiencing chemotherapy-induced neutropenia. Through these programs, Enveric seeks to establish differentiated clinical profiles and formulation advantages over existing psychedelic or synthetic counterparts.
Founded in 2019 under the name Psyched Wellness and rebranded as Enveric Biosciences in 2021, the company was cofounded by Gregory Chodakewitz, MD, who serves as Chief Executive Officer. Dr. Chodakewitz brings extensive experience in oncology drug development and commercialization, having held leadership roles at Delcath Systems and other life science ventures. The executive team and board of directors combine expertise in biotechnology, clinical research, regulatory affairs, and pharmaceutical manufacturing, providing strategic direction for advancing Enveric’s asset portfolio through clinical proof-of-concept and eventual regulatory approval.
Enveric has forged collaborations with leading academic institutions and contract research organizations to conduct its clinical trials, drawing on a network of scientific advisors and therapeutic experts. By focusing on the unique pharmacological properties of psychedelic molecules, the company aims to address unmet medical needs in mental health and oncology supportive care. Enveric is committed to rigorous clinical research standards and regulatory engagement as it progresses its programs toward pivotal trials and potential commercialization in key markets across the United States and Europe.
AI Generated. May Contain Errors.
Free SPZR Stock Alerts